1. Pink Sheet
  2. >>Agency Leadership

Lauren Silvis To Depart US FDA, Adding To High-Level String Of Agency Turnover In 2019

 
• By Michael Cipriano

Lauren Silvis will leave her post as chief of staff at the US FDA in the next several weeks, when she will be replaced by associate commissioner for strategic initiatives and external affairs Keagan Lenihan.

FDAEntrance_1200x675
Turnover among senior FDA leaders continues to mount in 2019.

The list of high-level staffers departing the US Food and Drug Administration in 2019 continues to grow, with chief of staff Lauren Silvis becoming the latest set to leave her post at the agency.

Silvis, who previously served as deputy center director for policy at the Center for Devices and Radiological Health, will leave...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.